



MROQC Lung Project: Clinical Tip Sheet

Lung Eligibility Criteria

Inclusion Criteria:

- **Newly diagnosed**, non-small cell, lung cancer patients
- **To be treated with a curative intent** with thoracic definitive radiotherapy
- Patients with previous lung surgery not related to their current lung cancer diagnosis or those who have surgery after completing radiation therapy.
- Patients treated with or without concurrent or sequential chemotherapy are eligible

Exclusion Criteria:

- Patients with metastatic disease (see SE1 data dictionary for further clarification)
- Patients who have been previously treated with radiation to the thoracic region
- Small-cell lung cancer patients
- Post-operative lung cancer patients, that have had lung surgery related to their current diagnosis.
- Patients with a second active cancer who have received or will receive therapy within 12 months of their anticipated radiation start date for their lung cancer.

Additional inclusion and exclusion criteria are listed on page 2 of the breast and lung eligibility criteria document.

Lung Cancer	MROQC Eligibility
Adenosquamous carcinoma	Included
Basaloid Squamous Cell Carcinoma	Included
Brachytherapy	Excluded
Carcinoid Tumor	Excluded
IMPT (Intensity- Modulated Proton Therapy)	Excluded
IORT (Intraoperative Radiotherapy)	Excluded
Mesothelioma	Excluded
Bilateral SBRT	Excluded

Data Collection Timeline and forms

Time Points	Pre-RT Eval	1 st Week of RT	Weekly (submit each week)	Last Week of Tx	1 mo. After RT	3 mo. After RT	6 mo. After RT	Annual (1-3 years post EOT date)
Patient	L1	x	L2	L3	L3	L3	L3	X
CDA	L4	x	x	L5	X	L10	L10	L11
Provider	x	L6	L7	L8	L9	L9	L9	x

SBRT (≤5 fractions) /Hypo fractionation (6-20 fractions): Timeline and Forms*

**For those SBRT/Hypo-fractionated patients following a modified follow-up schedule, the 1-month follow-up form is not needed. Complete the 3 and 6-month follow-up forms, the EOT date on the L8, and all other required forms.*

Time Points	Pre-RT Eval	1 st Week of RT	Last Week of Tx	1 mo. After RT	3 mo. After RT	6 mo. After RT	Annual (1-3 years post EOT date)
Patient	L1	x	x	X	L3	L3	x
CDA	L4	x	L5	X	L10	L10	L11
Provider	x	L6	L8 (EOT date only)	x	L9	L9	x

Project Upgrade Dates

Version #	Upgrade Date
V1 → V2	January 2014
V2 → V3	August 28 th , 2017
V3 → V4	May 7 th , 2019
V4 → V5	February 17 th , 2021

Project Changes

- **Update 12/8/25:** L1: Swallowing and education questions moved, L3: Two smoking questions removed and one new one added, L4: Previous Lung surgery response option revised, L6: Nodal staging question updated, L11: Disease status response option updated & COVID questions removed.
- **Update 10/20/25:** Patients with a second active cancer who have received or will receive therapy within 12 months of their anticipated lung radiation start date, are excluded from the project.
- **Update 3/7/25:** New demographic form added & demographic questions removed from L1.
- **Update 12/9/22:** Cannabis questions updated on patient forms, L1 & L3
- **Update 6/28/2022:** New cannabis-use questions added to L1 & L3 forms, a smoking cessation question added to L4 & thoracic RT question added to L11.
- **2/17/21:** Excluded SCLC and Post-op patients & included SBRT cases



MROQC Lung Project: Clinical Tip Sheet

Reminders

- ***SBRT/Hypo fractionated** Patients have adjusted collection time points, see the timeline above.
- **Post-op patients** refer to any patient who has had surgery on the lung that is being radiated PRIOR to enrollment. If the patient is to have surgery after radiation, or if prior surgery is not related to the current diagnosis, they are still included.
- **Follow-up data time points** do not have to be exact (i.e., exactly at 3 months). **Please collect as much follow-up data as possible**, even if it is not at the scheduled time point.
- **CDA forms** MUST always be completed. If a provider form is not completed, please answer the questions that are documented in the medical records/treatment plans.
- **L11 Annual Forms:** a patient appointment is not required. The form should be completed by chart abstraction and signed by the treating physician. Before submitting an SE2 form, the L11 form should be completed if not already submitted.